The Company will be focusing on the following programs with Bucillamine: Revive is targeting nerve agent exposure as its initial indication for its medical countermeasures program. Nerve agents are ...

The gross proceeds of approximately EUR 0.25 million will be used to fund business operations.

Dry January is mostly pain and not so much gain, says our writer. It’s month two and three that you really start to enjoy the ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Our grey matter has always been a mystery, even to neurologists, but Professor Masud Husain says life-changing advances may ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Problems with chemical messengers like dopamine were tied to posture issues in SMA in a mouse study, but levodopa therapy may ease symptoms.

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

The agreement will allow Enigma to use its PET imaging tracer PMI04 to visualize microglia activity in neurodegenerative ...